Background: Laparoscopic-assisted colectomy (LAC) for colorectal cancer has been shown to improve short-term outcomes compared with open colectomy (OC) in colorectal cancer patients. However, there are a few reports that describe the efficacy of LAC in the very elderly population. We investigated whether LAC improves short-term outcomes in elderly patients, especially those 80 years of age or older.
Method: Eighty-two consecutive elderly (80 years of age or older) patients who underwent either OC or LAC for colorectal cancer were reviewed. Continuous variables were analyzed by the Mann-Whitney U test. Categorical variables were compared by χ tests.
Results: Of the 82 elderly patients with colorectal cancer, 34 patients underwent OC and 48 patients had LAC. There were no significant differences in postoperative complications between the 2 groups. LAC demonstrated less blood loss, fewer days on a liquid diet, and a shorter postoperative stay in the hospital than OC.
Conclusions: LAC improved short-term outcomes even in very elderly patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/SLE.0b013e31828e3da5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic value of carcinoembryonic antigen in colorectal adenocarcinoma: expanding hypotheses into clinical practice.
Clin Exp Med
January 2025
Liver & Peritonectomy Unit, Department of Surgery, St George Hospital, Pitney Building, Short Street, Kogarah, NSW, 2217, Australia.
Purpose: This study seeks to resolve a fundamental question in oncology: Why do appendiceal and colorectal adenocarcinomas exhibit distinct liver metastasis rates? Building on our prior hypothesis published in the British Journal of Surgery, our institution has investigated potential DNA mutations within the carcinoembryonic antigen-related cell adhesion molecule (CEACAM5) gene's Pro-Glu-Leu-Pro-Lys (PELPK) motif to evaluate its role as a biomarker for liver metastasis risk.
Methods: Partnering with the Australian Genome Research Facility, the PELPK motif of CEACAM5 was analysed in colorectal and appendiceal adenocarcinomas to detect DNA mutations associated with liver metastasis. Additionally, our institution performed the COPPER trial to assess carcinoembryonic antigen (CEA) levels in portal versus peripheral blood in patients with appendiceal adenocarcinoma and a systematic review and meta-analysis of 136 studies on CEA's prognostic significance among patients with colorectal and appendiceal adenocarcinoma.
Impact of perforation following self-expandable metal stent as a bridge to surgery for malignant colorectal obstruction: a multicenter study of the Research Group for Stent in the Korean Society of Gastrointestinal Endoscopy.
Surg Endosc
January 2025
Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Background And Aims: Self-expandable metal stents (SEMS) are effective in alleviating malignant colorectal obstruction. However, bowel perforation following SEMS placement remains a significant concern, as it can adversely affect oncological outcomes. This study aimed to evaluate the recurrence and overall survival rates associated with SEMS-related bowel perforations.
View Article and Find Full Text PDFThe effect of fecal bile acids on the incidence and risk-stratification of colorectal cancer: an updated systematic review and meta-analysis.
Sci Rep
January 2025
Department of Colorectal Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo, 315000, China.
Recent studies suggest the role of gut microbes in bile acid metabolism in the development and progression of colorectal cancer. However, the surveys of the association between fecal bile acid concentrations and colorectal cancer (CRC) have been inconsistent. We searched online to identify relevant cross-sectional and case-control studies published online in the major English language databases (Medline, Embase, Web of Science, AMED, and CINAHL) up to January 1, 2024.
View Article and Find Full Text PDFValue of ctDNA in surveillance of adjuvant chemosensitivity and regimen adjustment in stage III colon cancer: a protocol for phase II multicentre randomised controlled trial (REVISE trial).
BMJ Open
January 2025
Colorectal Cancer Center, Department of General Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan, China
Introduction: The standard of care for stage III colon cancer is 3 or 6 months of double-drug regimen chemotherapy following radical surgery. However, patients with positive circulating tumour DNA (ctDNA) exhibit a high risk of recurrence risk even if they receive standard adjuvant chemotherapy. The potential benefit of intensified adjuvant chemotherapy, oxaliplatin, irinotecan, leucovorin and fluoropyrimidine (FOLFOXIRI), for ctDNA-positive patients remains to be elucidated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!